Cancer Registry Software Market Size, Share and Growth Outlook, 2026

Cancer Registry Software Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer Registry Software Market size is forecast to increase from $112.8 Million in 2026 to $243.56 Million in 2034 at a CAGR of 10.1% between 2026 and 2034.

The Cancer Registry Software market report provides detailed analysis and outlook of Cancer Registry Software segments including By Software Type (Standalone Software, Integrated Software), By Database (Public Data, Commercial Data), By Deployment Model (Cloud-based, On-premises), By Functionality (Data Collection and Management, Reporting and Compliance, Analytics and Visualization, Patient Tracking, Others), By End-User (Hospitals and Medical Practices, Government Organizations, Research Centers, Pharmaceutical and Biotechnology Companies, Private Players) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer Registry Software Industry Overview

Digital Transformation Driving Modern Cancer Data Management

The cancer registry software industry is undergoing substantial modernization as healthcare organizations seek more efficient methods for collecting, managing, analyzing, and reporting oncology data. Cancer registries play a critical role in tracking cancer incidence, treatment outcomes, survival trends, and population health metrics. Growing regulatory requirements, expanding oncology datasets, and increasing reliance on real-time clinical intelligence are accelerating the adoption of advanced cancer registry software platforms. Healthcare providers are increasingly prioritizing solutions that improve data accuracy, streamline reporting workflows, and support compliance with national and regional cancer surveillance standards.

Strategic Consolidation Enhancing Registry Data Capabilities

Industry consolidation is strengthening the capabilities of cancer registry software providers. Healthcare revenue cycle and clinical data management company Savista entered into a definitive agreement to acquire the Cancer Registry Services Division of ONCO. The transaction combines Savista’s cloud-based healthcare infrastructure with ONCO’s established cancer abstracting software technologies. The integration is designed to enhance reporting precision, improve longitudinal oncology tracking, and support high-volume cancer data management across major North American hospital networks. This development reflects the growing demand for comprehensive registry platforms capable of supporting increasingly complex oncology reporting requirements while improving operational efficiency.

Regulatory Compliance Driving Software Upgrades

Cancer registry software vendors and healthcare institutions continue to invest in technology modernization to align with evolving reporting standards. The Spencer Fox Eccles School of Medicine implemented a comprehensive upgrade of its cancer registry software infrastructure to comply with mandatory NAACCR Version 26 guidelines. The updated platform includes a redesigned user interface, a dedicated performance dashboard for Oncology Data Specialists (ODS), and an automated single-button geocoding module that simplifies demographic data reporting. These enhancements are intended to streamline preparation for mandatory state and national cancer database submissions while improving user productivity and data quality management.

Cloud-Based Platforms Improving Reporting Efficiency

The industry is witnessing a significant migration from traditional on-premises registry systems toward cloud-native and hybrid deployment environments. Hospital operational metrics demonstrated that public health organizations and municipal healthcare networks utilizing web-based cancer registry software achieved approximately 25% higher cross-department reporting efficiency. This improvement has been largely attributed to real-time Electronic Health Record (EHR) integration capabilities and automated data ingestion workflows. As healthcare systems continue to prioritize interoperability, cloud adoption, and data accessibility, modern cancer registry software platforms are becoming increasingly important tools for population health surveillance, clinical research, and oncology program management.

Cancer Registry Software Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer Registry Software market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- IBM Corporation, McKesson Corporation, Elekta AB, Flatiron Health (Roche), Cerner Corporation (Oracle), Epic Systems Corporation, Conduent Inc., GE HealthCare, OncoHealth, Rocky Mountain Cancer Data Systems. The Cancer Registry Software market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer Registry Software industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer Registry Software Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer Registry Software companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer Registry Software markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer Registry Software Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer Registry Software industry include- IBM Corporation, McKesson Corporation, Elekta AB, Flatiron Health (Roche), Cerner Corporation (Oracle), Epic Systems Corporation, Conduent Inc., GE HealthCare, OncoHealth, Rocky Mountain Cancer Data Systems. The Cancer Registry Software market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer Registry Software Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer Registry Software market remains one of the strongest-performing segments in the country.
The US Cancer Registry Software Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer Registry Software market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer Registry Software industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer Registry Software markets

Canada's strong Cancer Registry Software sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer Registry Software market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer Registry Software Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer Registry Software market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer Registry Software population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer Registry Software industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer Registry Software market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer Registry Software sales through 2034

France Cancer Registry Software companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer Registry Software Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer Registry Software distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer Registry Software Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer Registry Software market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer Registry Software industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer Registry Software industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer Registry Software Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer Registry Software market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer Registry Software market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer Registry Software Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer Registry Software Market Segmentation

By Software Type
Standalone Software
Integrated Software
By Database
Public Data
Commercial Data
By Deployment Model
Cloud-based
On-premises
By Functionality
Data Collection and Management
Reporting and Compliance
Analytics and Visualization
Patient Tracking
Others
By End-User
Hospitals and Medical Practices
Government Organizations
Research Centers
Pharmaceutical and Biotechnology Companies
Private Players

Top Companies in Cancer Registry Software Industry

IBM Corporation
McKesson Corporation
Elekta AB
Flatiron Health (Roche)
Cerner Corporation (Oracle)
Epic Systems Corporation
Conduent Inc.
GE HealthCare
OncoHealth
Rocky Mountain Cancer Data Systems

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

MoCRA Compliance as a Competitive Advantage in the US

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025